Skip to content

Keros Therapeutics, Inc.

KROS· NasdaqCore metricsCIK 1664710

Pharmaceutical preparations553 peers

Last sale
Nov 12, 2026 · +5.79%
Market cap
$197.22M
19.62M shares
Filings
538
$40.01M
Q3 2026+6,775.0% FY25 yoy
$14.15M
Q3 2026N/M FY25 yoy
$12.82M
Q3 2026N/M FY25 yoy
-$20.85M
Q3 2026derivedN/M FY25 yoy
$0.70
Q3 2026N/M FY25 yoy
$259.46M
Q3 2026−48.7% FY25 yoy
$197.22M
—
4.8×
0.7×
-24.48%
—

Twelve months to Sep 30, 2026 · derived

Price

$10.0540.53%$6.85past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$244.06MFY 2025
$244.06M0FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$244,061,000reported
FY 20242024-12-31$3,550,000reported
FY 20232023-12-31$151,000reported
FY 20222022-12-31$0reported
FY 20212021-12-31$20,100,000reported
FY 20202020-12-31$0reported
FY 20192019-12-31$10,000,000reported

Capital returns

Dividends and buybacks · FY2024 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025—$375.00M$375.00M—19.72M sh−51.4%353.9%
FY2024—$0.00$0.00—40.56M sh+12.7%—

Segments

Products
Revenue by Products, FY2021 to FY2025FY2021License revenue · FY2021 · $20.10MFY2022FY2023Service and other revenue · FY2023 · $151.00KFY2024License revenue · FY2024 · $3.00MService and other revenue · FY2024 · $550.00KService revenue · FY2024 · $3.00MFY2025License revenue · FY2025 · $205.36MService and other revenue · FY2025 · $38.71MService revenue · FY2025 · $38.50M
LineFY2025ShareChange
License revenue$205.36M84%+6,745.2%
Service and other revenue$38.71M16%+6,937.5%
Service revenue$38.50M16%+1,183.3%
Total$244.06M

From the 10-K filed Mar 4, 2026KROS

Pharmaceutical preparations

Keros Therapeutics, Inc. is the 78th largest of the 554 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Keros Therapeutics, Inc. · CIK 1664710 · Engraved from SEC EDGAR